Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs 675

Quick answer

Neurology & CNS: NovaPharmaNews indexes 675 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Pipeline programs

Page 10 of 15

  1. fetal nigral transplantation

    Ultragenyx UK Limited

    Parkinson Disease

    phase 2 other completed

    1 trial

  2. glatiramer acetate 20 mg

    Teva Pharma GmbH

    Relapse-Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  3. glatiramer acetate 20 mg

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  4. glatiramer acetate with minocycline

    Teva Pharma GmbH

    Relapse Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  5. laquinimod 0.3

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  6. levodopa

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  7. methylprednisolone

    Teva Pharma GmbH

    Multiple Sclerosis (MS)

    phase 2 small molecule terminated

    1 trial

  8. mutual support group

    Hong Kong Baptist University

    Schizophrenia

    phase 2 other completed

    1 trial

  9. pallidotomy

    Ultragenyx UK Limited

    Parkinson Disease

    phase 2 other completed

    1 trial

  10. pioglitazone

    Takeda

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  11. sabirnetug

    Acumen Pharmaceuticals

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  12. sarcosine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  13. sodium oxybate

    Jazz Pharmaceuticals Ireland Limited

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  14. 14-XC-CL

    Lacuna Pharma Pty Ltd

    Parkinson’s Disease

    phase 1 other active

    1 trial

  15. 300 mg [C14] CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  16. 3135003

    Orion Laboratories Pty.

    Parkinson desease

    phase 1 other active

    1 trial

  17. 3135004

    Orion Laboratories Pty.

    Parkinson disease

    phase 1 other active

    1 trial

  18. 50mg Ezogabine/retigabine

    GlaxoSmithKline

    Epilepsy

    phase 1 small molecule completed

    1 trial

  19. 63733657EDI1003

    Janssen-Cilag International N.V.

    Alzheimer's Disease (Healthy Participants)

    phase 1 other active

    1 trial

  20. A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants

    Merck Sharp and Dohme

    Amyotrophic lateral sclerosis and Alzheimer’s disease

    phase 1 other active

    1 trial

  21. A randomised for Depression, Cognitive dysfuncti…

    Lacuna Pharma Pty Ltd

    Depression, Cognitive dysfunction, Alzheimer’s disease

    phase 1 other active

    1 trial

  22. A study to find out how healthy people tolerate a new drug called S221237.

    The George Institute

    Parkinson disease (PD)

    phase 1 other active

    1 trial

  23. ACTOS (Pioglitazone)

    Takeda

    Multiple Sclerosis, Relapsing-Remitting

    phase 1 small molecule completed

    1 trial

  24. ACU193

    Acumen Pharmaceuticals

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  25. ALN-5288

    Alnylam Netherlands B.V.

    Alzheimer's Disease

    phase 1 small molecule active

    1 trial

  26. ALN-5288-001

    Alnylam Netherlands B.V.

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  27. ALN-APP

    Alnylam Netherlands B.V.

    Early-Onset Alzheimer Disease

    phase 1 small molecule active

    1 trial

  28. ALN-APP-001

    Alnylam Netherlands B.V.

    Early-onset Alzheimer's disease (EOAD)

    phase 1 other active

    1 trial

  29. ALN-SNCA

    Regeneron UK Limited

    Parkinsons Disease

    phase 1 small molecule active

    1 trial

  30. ALN-SNCA-PD-2482

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 1 other active

    1 trial

  31. AUTO1-MS1

    Autolus GmbH

    Refractory Progressive Multiple Sclerosis

    phase 1 other active

    1 trial

  32. BIA-28-6156-111

    Bial Portela & Companhia S.A.

    Parkinson's disease

    phase 1 other active

    1 trial

  33. BIIB094

    IONIS PHARMACEUTICALS INC

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  34. BIS-001 ER

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy, Complex Partial

    phase 1 small molecule completed

    1 trial

  35. BN44083

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  36. BP42230

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  37. BP45211

    Hoffmann-La Roche

    Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  38. BP45361

    Hoffmann-La Roche

    Parkinson’s Disease

    phase 1 other active

    1 trial

  39. BRIVA-10-24

    Lacuna Pharma Pty Ltd

    Epilepsy

    phase 1 other active

    1 trial

  40. BXCL501 80 Micrograms

    BioXcel Therapeutics

    Schizophrenia

    phase 1 small molecule active

    1 trial

  41. Bioequivalence of Cladribine 10 mg from two different products

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers. The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).

    phase 1 other active

    1 trial

  42. CA061-1006

    Celgene Europe Limited

    Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)

    phase 1 other active

    1 trial

  43. CDLX313A12101

    Novartis Pharmaceuticals

    Parkinson’s Disease

    phase 1 other active

    1 trial

  44. CERE-110: Adeno-Associated Virus Delivery of NGF

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 1 gene therapy completed

    1 trial

  45. CERE-120: AAV2-NTN

    SANGAMO THERAPEUTICS, INC

    Parkinson's Disease

    phase 1 gene therapy completed

    1 trial

  46. CN0140003

    Bristol-Myers Squibb Australia Pty Ltd

    Neuropsychiatric indications and potentially other conditions

    phase 1 other active

    1 trial

  47. CNCT19 cell injection

    Juventas Cell Therapy

    Neurological Autoimmune Diseases

    phase 1 mab active

    1 trial

  48. Carbidopa

    United Therapeutics Europe Ltd

    Multiple Sclerosis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

675 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.